Disulfiram has been used for more than 50 years as an aversion therapeutic agent in the treatment of alcohol dependence (2). However, categorizing disulfiram as a "psychological pill" does not encompass the whole potential of the substance, since emerging evidence suggests that it also possesses anticraving properties (3). Besides its well-known mechanism of action (i.e., aldehyde dehydrogenase inhibition), disulfiram also inhibits dopamine beta-hydroxylase, leading to an increase of dopamine concentrations while decreasing concentrations of norepinephrine in the brain (4). Since dopaminergic transmission in the ventral striatal reward system is suggested to play a key role in the development of addictive disorders and craving (5, 6) and reduced activation of this system has been shown in alcohol dependence (7), cocaine dependence (8), and non-substance-related addictions such as pathological gambling (9), disulfiram could be hypothesized as a common treatment option for these disorders. In cocaine dependence, disulfiram has already shown preliminary efficacy in reducing craving and relapse rates (10). Furthermore, in a patient with alcohol dependence and comorbid pathological gambling, treatment with disulfiram led to a significant reduction in alcohol craving and urges to gamble as well as to maintenance of abstinence from both alcohol and gambling for more than 12 months (11). In alcohol dependence, most of the clinical trials conducted with disulfiram have possessed significant methodological shortcomings and have not measured changes in alcohol craving under treatment (2). Therefore, to evaluate the potential of disulfiram as an anticraving agent also in alcohol dependence, further randomized controlled trials would be needed.